What is Allozymes?
Allozymes operates at the intersection of biotechnology and advanced engineering, specializing in the rapid discovery and optimization of enzymes. By utilizing a proprietary microfluidics platform, the company achieves unprecedented throughput in enzyme screening, allowing for the development of bespoke biosolutions that are both environmentally sustainable and commercially viable. Their market position is defined by a versatile service model that spans the pharmaceutical, food and nutrition, and chemical sectors, effectively replacing legacy, resource-intensive processes with high-efficiency biological alternatives. This technological edge enables Allozymes to act as a critical partner for enterprises aiming to meet stringent sustainability mandates while maintaining operational excellence.
How much funding has Allozymes raised?
Allozymes has raised a total of $20M across 2 funding rounds:
Angel/Seed
$5M
Series A
$15M
Angel/Seed (2021): $5M with participation from TI Platform Management, HAX, Entrepreneur First, and Xora Innovation
Series A (2024): $15M led by Entrepreneur First, Seventure Partners, and SOSV
Key Investors in Allozymes
Entrepreneur First
Entrepreneur First is an international Talent Investor, which supports individuals to build technology companies. The company was established in 2011 and is headquartered out of London, UK.
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable blue economy initiatives.
SOSV
SOSV is a multi-stage venture capital investor that provides intellectual and financial capital to accelerate founders big ideas.
What's next for Allozymes?
With the recent influx of capital, Allozymes is poised to scale its engineering capabilities and deepen its penetration into high-growth life science verticals. The strategic roadmap likely involves expanding the company's library of proprietary enzymes and enhancing its licensing infrastructure to support broader industrial adoption. As the firm continues to refine its microfluidics technology, the focus will shift toward commercializing these innovations at scale, potentially disrupting traditional bioremediation and personal care supply chains. Investors are closely monitoring the company's ability to translate its technical milestones into long-term revenue growth, particularly as it navigates the complexities of global regulatory environments and competitive biotechnology landscapes.
See full Allozymes company page
